RNA interference technology for anti-VEGF treatment

Chen, Shun; Feng, Jia; Ma, Liuqing; Liu, Zhenguo; Yuan, Weien

doi:10.1517/17425247.2014.926886

Cited by 22 publications

(15 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31,36,37 In the current study, we designed two siRNAs to specifically knock down the gene GNAQ, mutation of which is thought to encode the factor that initiates the malignant transformation of UM. 31,36,37 In the current study, we designed two siRNAs to specifically knock down the gene GNAQ, mutation of which is thought to encode the factor that initiates the malignant transformation of UM.…”

Section: Discussionmentioning

confidence: 99%

The oncolytic virus H101 combined with GNAQ siRNA‐mediated knockdown reduces uveal melanoma cell viability

Qiu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background Uveal melanoma (UM) is a severe human malignancy with a high mortality rate, as well as high metastasis and recurrence potential. The active mutation of G protein subunit alpha q (GNAQ) or G protein subunit alpha 11 (GNA11) is a major trigger for UM. Oncolytic adenovirus H101 (H101) is the first oncolytic virus approved for clinical applications in cancer therapy by the China Food and Drug Administration. We investigated whether combining H101 with the downregulation of GNAQ expression would act synergistically in UM therapy. Methods Three UM cell lines OMM2.3 and 92.1, harboring GNAQ mutation, and OCM1, harboring B‐Raf proto‐oncogene mutation, were chosen for our research. The cellular toxicity of adenoviral infection and the cell growth rate were measured with a Cell Counting Kit‐8. Western blot analysis was used to detect GNAQ, p‐MEK1/2, YAP, and p‐YAP expression. The apoptosis and cell‐cycle distribution of cells were evaluated with annexin‐V and propidium iodide staining. Results Our results revealed that OMM2.3 and 92.1 cells were more sensitive to H101 infection than OCM1 cells. GNAQ expression was markedly reduced by small interfering RNA, siGNAQ. Combined treatment of siGNAQ and H101 inhibited the proliferation and activated the apoptosis of OMM2.3 and 92.1 cells by blocking the phosphorylation of MEK1/2 and increasing the phosphorylation of YAP. Conclusions In summary, a therapy combining H101 and siGNAQ is feasible, with potential utility as a novel targeted molecular therapy for UM, especially those carrying a GNAQ mutation.

show abstract

Section: Discussionmentioning

confidence: 99%

The oncolytic virus H101 combined with GNAQ siRNA‐mediated knockdown reduces uveal melanoma cell viability

Qiu

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…The non-viral vector mediates gene transfection were no longer limited by the capacity of gene material. Non-viral mediates delivery methods including electroporation, microneedles, polyethylenimine (PEI), polymersomes, polyspermine, the use of branched molecules and cationic lipid-mediates delivery (Boado, 2007; De Vry et al, 2010; Duan et al, 2012; Xiang et al, 2012; Ma et al, 2013; Chen et al, 2014, 2016a,b; Ge et al, 2014a,b; Peng et al, 2014; Che et al, 2016; Song et al, 2016). …”

Section: Delivery Methods Of Gene Therapymentioning

confidence: 99%

Current Experimental Studies of Gene Therapy in Parkinson's Disease

Lin

Xie

Zhang

et al. 2017

Front. Aging Neurosci.

Self Cite

View full text Add to dashboard Cite

Parkinson's disease (PD) was characterized by late-onset, progressive dopamine neuron loss and movement disorders. The progresses of PD affected the neural function and integrity. To date, most researches had largely addressed the dopamine replacement therapies, but the appearance of L-dopa-induced dyskinesia hampered the use of the drug. And the mechanism of PD is so complicated that it's hard to solve the problem by just add drugs. Researchers began to focus on the genetic underpinnings of Parkinson's disease, searching for new method that may affect the neurodegeneration processes in it. In this paper, we reviewed current delivery methods used in gene therapies for PD, we also summarized the primary target of the gene therapy in the treatment of PD, such like neurotrophic factor (for regeneration), the synthesis of neurotransmitter (for prolong the duration of L-dopa), and the potential proteins that might be a target to modulate via gene therapy. Finally, we discussed RNA interference therapies used in Parkinson's disease, it might act as a new class of drug. We mainly focus on the efficiency and tooling features of different gene therapies in the treatment of PD.

show abstract

“…Also, genome editing tools, such as RNAi or CRISPR/Cas9 systems, facilitate preclinical target discovery and validation [68,69], using either comprehensive panels of cell line models across tissue types or patient-derived cell samples in genetically selected patient populations. These exciting genome-engineering tools may even provide effective and safe therapeutic applications in the future, provided that RNAi-based delivery or CRISPR/ Cas9 systems can be improved in terms of their fidelity and selectivity to target a specific part and tissue context of the disease network only [70,71].…”

Section: Future Directions: Incorporating Genetic Variation Into the mentioning

confidence: 99%

Identification of drug candidates and repurposing opportunities through compound–target interaction networks

Cichońska

Rousu

Aittokallio

2015

Expert Opinion on Drug Discovery

View full text Add to dashboard Cite

Although the studies reviewed here have already demonstrated that network-centric modeling approaches have the potential to identify candidate compounds and selective targets in disease networks, many challenges still remain. In particular, these challenges include how to incorporate the cellular context and genetic background into the disease networks to enable more stratified and selective target predictions, as well as how to make the prediction models more realistic for the practical drug discovery and therapeutic applications.

show abstract

RNA interference technology for anti-VEGF treatment

Abstract: RNAi technology has a promising future in anti-VEGF treatment, most of the investigations are encouraging and exciting. More anti-VEGF candidates will enter clinical trials and may be a novel therapeutic strategy.

Cited by 22 publications

References 81 publications

The oncolytic virus H101 combined with GNAQ siRNA‐mediated knockdown reduces uveal melanoma cell viability

The oncolytic virus H101 combined with GNAQ siRNA‐mediated knockdown reduces uveal melanoma cell viability

Current Experimental Studies of Gene Therapy in Parkinson's Disease

Identification of drug candidates and repurposing opportunities through compound–target interaction networks

Contact Info

Product

Resources

About